The peripheral blood immune cell profile in a teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia

A teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia was hospitalized and recovered in 15 days. The immunophenotyping analysis of peripheral blood cells was performed in two time points: the first was 1 month before (pre-infection) while the second was during COVID-19 pneumonia...

Descripción completa

Detalles Bibliográficos
Autores principales: Ciardi, Maria Rosa, Zingaropoli, Maria Antonella, Pasculli, Patrizia, Perri, Valentina, Tartaglia, Matteo, Valeri, Serena, Russo, Gianluca, Conte, Antonella, Mastroianni, Claudio Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7361089/
https://www.ncbi.nlm.nih.gov/pubmed/32688146
http://dx.doi.org/10.1016/j.jneuroim.2020.577323
_version_ 1783559340391661568
author Ciardi, Maria Rosa
Zingaropoli, Maria Antonella
Pasculli, Patrizia
Perri, Valentina
Tartaglia, Matteo
Valeri, Serena
Russo, Gianluca
Conte, Antonella
Mastroianni, Claudio Maria
author_facet Ciardi, Maria Rosa
Zingaropoli, Maria Antonella
Pasculli, Patrizia
Perri, Valentina
Tartaglia, Matteo
Valeri, Serena
Russo, Gianluca
Conte, Antonella
Mastroianni, Claudio Maria
author_sort Ciardi, Maria Rosa
collection PubMed
description A teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia was hospitalized and recovered in 15 days. The immunophenotyping analysis of peripheral blood cells was performed in two time points: the first was 1 month before (pre-infection) while the second was during COVID-19 pneumonia (infection). At the infection time point, no differences in the percentages of immune activation and immunesenescence of CD4+ and CD8+ T-cells were observed compared to the pre-infection time point. Our evaluation seems to confirm that teriflunomide controls T-cells immune activation and immunosenescence suggesting that teriflunomide should not be discontinued in MS patients with an active COVID-19 pneumonia.
format Online
Article
Text
id pubmed-7361089
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-73610892020-07-15 The peripheral blood immune cell profile in a teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia Ciardi, Maria Rosa Zingaropoli, Maria Antonella Pasculli, Patrizia Perri, Valentina Tartaglia, Matteo Valeri, Serena Russo, Gianluca Conte, Antonella Mastroianni, Claudio Maria J Neuroimmunol Article A teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia was hospitalized and recovered in 15 days. The immunophenotyping analysis of peripheral blood cells was performed in two time points: the first was 1 month before (pre-infection) while the second was during COVID-19 pneumonia (infection). At the infection time point, no differences in the percentages of immune activation and immunesenescence of CD4+ and CD8+ T-cells were observed compared to the pre-infection time point. Our evaluation seems to confirm that teriflunomide controls T-cells immune activation and immunosenescence suggesting that teriflunomide should not be discontinued in MS patients with an active COVID-19 pneumonia. Elsevier B.V. 2020-09-15 2020-07-15 /pmc/articles/PMC7361089/ /pubmed/32688146 http://dx.doi.org/10.1016/j.jneuroim.2020.577323 Text en © 2020 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Ciardi, Maria Rosa
Zingaropoli, Maria Antonella
Pasculli, Patrizia
Perri, Valentina
Tartaglia, Matteo
Valeri, Serena
Russo, Gianluca
Conte, Antonella
Mastroianni, Claudio Maria
The peripheral blood immune cell profile in a teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia
title The peripheral blood immune cell profile in a teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia
title_full The peripheral blood immune cell profile in a teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia
title_fullStr The peripheral blood immune cell profile in a teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia
title_full_unstemmed The peripheral blood immune cell profile in a teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia
title_short The peripheral blood immune cell profile in a teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia
title_sort peripheral blood immune cell profile in a teriflunomide-treated multiple sclerosis patient with covid-19 pneumonia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7361089/
https://www.ncbi.nlm.nih.gov/pubmed/32688146
http://dx.doi.org/10.1016/j.jneuroim.2020.577323
work_keys_str_mv AT ciardimariarosa theperipheralbloodimmunecellprofileinateriflunomidetreatedmultiplesclerosispatientwithcovid19pneumonia
AT zingaropolimariaantonella theperipheralbloodimmunecellprofileinateriflunomidetreatedmultiplesclerosispatientwithcovid19pneumonia
AT pascullipatrizia theperipheralbloodimmunecellprofileinateriflunomidetreatedmultiplesclerosispatientwithcovid19pneumonia
AT perrivalentina theperipheralbloodimmunecellprofileinateriflunomidetreatedmultiplesclerosispatientwithcovid19pneumonia
AT tartagliamatteo theperipheralbloodimmunecellprofileinateriflunomidetreatedmultiplesclerosispatientwithcovid19pneumonia
AT valeriserena theperipheralbloodimmunecellprofileinateriflunomidetreatedmultiplesclerosispatientwithcovid19pneumonia
AT russogianluca theperipheralbloodimmunecellprofileinateriflunomidetreatedmultiplesclerosispatientwithcovid19pneumonia
AT conteantonella theperipheralbloodimmunecellprofileinateriflunomidetreatedmultiplesclerosispatientwithcovid19pneumonia
AT mastroianniclaudiomaria theperipheralbloodimmunecellprofileinateriflunomidetreatedmultiplesclerosispatientwithcovid19pneumonia
AT ciardimariarosa peripheralbloodimmunecellprofileinateriflunomidetreatedmultiplesclerosispatientwithcovid19pneumonia
AT zingaropolimariaantonella peripheralbloodimmunecellprofileinateriflunomidetreatedmultiplesclerosispatientwithcovid19pneumonia
AT pascullipatrizia peripheralbloodimmunecellprofileinateriflunomidetreatedmultiplesclerosispatientwithcovid19pneumonia
AT perrivalentina peripheralbloodimmunecellprofileinateriflunomidetreatedmultiplesclerosispatientwithcovid19pneumonia
AT tartagliamatteo peripheralbloodimmunecellprofileinateriflunomidetreatedmultiplesclerosispatientwithcovid19pneumonia
AT valeriserena peripheralbloodimmunecellprofileinateriflunomidetreatedmultiplesclerosispatientwithcovid19pneumonia
AT russogianluca peripheralbloodimmunecellprofileinateriflunomidetreatedmultiplesclerosispatientwithcovid19pneumonia
AT conteantonella peripheralbloodimmunecellprofileinateriflunomidetreatedmultiplesclerosispatientwithcovid19pneumonia
AT mastroianniclaudiomaria peripheralbloodimmunecellprofileinateriflunomidetreatedmultiplesclerosispatientwithcovid19pneumonia

Ejemplares similares